Navigation Links
Cytopia Presentation on VDA CYT997 at AACR Conference
Date:4/15/2009

MELBOURNE, Australia, April 15 /PRNewswire/ -- Cytopia Limited (ASX: CYT) announced that it will present data on its anticancer vascular disrupting agent (VDA) CYT997 at the forthcoming 100th Annual Meeting of the American Association for Cancer Research, in Denver, Colorado, USA.

Dr David Segal, Principal Scientist at Cytopia, will be presenting the poster in the Late-Breaking Research: Experimental and Molecular Therapeutics 2 poster session on Tuesday, April 21, 2009 from 8:00 AM to 2:00 PM (US MDT), Hall BF, Poster Section 26, Poster Board 18.

The poster, entitled CYT997: Preclinical studies on the antivascular effects and mode of action of a Phase II vascular disrupting agent outlines extensive preclinical data for CYT997 which is currently in Phase II clinical studies. Data for CYT997 in a panel of in vitro and in vivo assays will be shown clearly demonstrating the potent antivascular and cytotoxic effects of the compound.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.

Website: www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
2. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
3. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
4. Cytopia and Other Progen Shareholders Maintain Call for Meeting
5. Cytopia Letter to Progen Shareholders
6. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
7. Strategic Diagnostics Updates Roth Conference Presentation Time
8. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
9. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
10. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
11. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/24/2016)... Israel , May 24, 2016   MedyMatch Technology ... physicians with artificial intelligence, real-time decision support tools in the ... present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed ... Israel,s 15th National Life Sciences and ... at the David Intercontinental Hotel in Tel Aviv, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, ... new Media Cybernetics corporate branding reflects a results-driven revitalization for a company with ... The re-branding components include a crisp, refreshed logo and a new web presence. ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):